Postoperative complications have been reported to be a risk factor for worse oncologic outcomes in patients with esophageal cancer. However, the impact of postoperative complications on prognosis ...
On November 22, 2024, PAVmed Inc. completed the sale of $21.95 million in principal amount of Lucid Diagnostics Inc.’s Senior Secured Convertible Notes, known as the “Lucid 2024 Convertible Notes,” in ...
The EC considered the treatment's activity in patients with advanced, PD-L1-positive esophageal and gastric cancers in the RATIONALE-305 and -306 trials.